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Natural urinary macromolecular inhibitors: Attenuation of inhibitory
activity by urate salts. The interaction between naturally occurring
urinary macromolecular inhibitors of calcium oxalate nucleation and
crystal growth and the various urate salts was explored in vitro. The
fraction of macromolecules chosen for the study was the one which was
previously shown to have a potent inhibitor activity against calcium
oxalate nucleation and one which gave a satisfactory yield. As little as
0.025 mg/mI of this fraction (Y-b) was found to inhibit calcium oxalate
nucleation by nearly 50% and crystal growth by 31%. Prior incubation
of the solution containing Y-b with increasing crystal surface areas (1.1
to 26.2 mm2/ml) of monosodium urate (NaU), monopotassium urate
(KU), or uric acid (UA) attenuated the inhibitory action of the Y-b
fraction for both nucleation and crystal growth of calcium oxalate. The
most prominent effect was elicited by NaU at surface areas as small as
1.1 mm2/ml. Potassium urate and UA were without significant effects
until surface areas of 13.1 and 2.6 mm2/ml, respectively, were achieved.
These results support an important pathogenetic role for urates (partic-
ularly NaU) in the development of hyperuricosuric calcium urolithiasis.
L'inhibiteurs des macromolecules urinaires normalement: Attenuation
de Ia activité inhibiteur par les sels d'urate. L'interaction entre les
inhibiteurs macromoléculaires normalement presents dans l'urine de Ia
nuclCation de l'oxalate de calcium et de Ia croissance cristalline et les
divers sels d'urate a été explorée in vitro. La fraction de macromol-
écules choisies pour l'ëtude étaient celle dont il avait ëté montrC
auparavant qu'elle était porteuse d'une activilC inhibitrice puissante
contre Ia nucleation d'oxalate de calcium ct celle qui donnait un
rendement satisfaisant. Une quantité aussi faible que 0,025 mg/mI de
cette fraction (Y-b) s'est avérée capable d'inhiber Ia nucleation d'oxa-
late de calcium d'environ 50% et Ia croissance cristalline de 31%. Une
incubation prealable d'une solution contenant Y-b avec des surfaces de
cristaux croissantes (1,! a 26,2 mm2/ml) d'urate monosodique (NaU),
d'urate monopotassique (KU), ou d'acide urique (UA) a atténué
l'action inhibitrice de Ia fraction Y-b sur Ia nucleation et Ia croissance
cristalline de l'oxalatc de calcium. L'effet Ic plus marqué était obtenu
par du NaU sur des surfaces aussi faibles que 1.1 mm2/ml. L'urate dc
potassium et l'UA étaient sans effet significatifjusqu'a des surfaces de
13,1 et 2,6 mm2/ml, respectivement. Ces résultats sont en faveur d'un
role physiopathologique important des urates (particulierement de
NaU) dans Ic dCveloppement de Ia lithiase urinaire calcique
hyperuricosurique.
The association of hyperuricosuria with calcium urolithiasis
has long been recognized [1, 2]. The clinical entity describing
this association has been termed hyperuricosuric calcium oxa-
late nephrolithiasis [3] or hyperuricosuric calcium urolithiasis
[4]. Recently, an important pathogenetic role of monosodium
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urate (NaU) has been implicated. The urinary environment was
found to be supersaturated with respect to NaU [5], a situation
favoring the formation of colloidal or crystalline form of this
urate salt. The NaU so-formed was then believed to directly
cause crystallization of calcium oxalate by inducing heteroge-
neous nucleation of calcium oxalate [6, 7] or indirectly by
binding glycosaminoglycans [8, 9] and attenuating their inhibi-
tion of aggregation [8, 10] and nucleation of calcium oxalate
[11].
Though attractive, the above scheme needs further validation
since other investigators have not observed reduced urine
inhibitors of calcium oxalate crystal growth in hyperuricosuria
[12]. In addition, the evidence for binding by urate and attenua-
tion of inhibitor activity was derived utilizing a model glycos-
aminoglycan (heparin), rather than a naturally occurring urinary
material. Further, there is some evidence that undissociated
uric acid (UA) may play a role in initiating calcium oxalate
crystallization. Although UA has been found to be less effective
than NaU in inducing heterogeneous nucleation of calcium
oxalate [6], its lattice dimensions show a better match with
those of calcium oxalate. Moreover, Coe [13] reported that
urinary pH in patients with hyperuricosuric calcium oxalate
nephrolithiasis was significantly lower than in control subjects.
Thus, the urinary concentration of UA increased significantly in
patients with hyperuricosuria. Despite reports to the contrary
[141, the above findings suggested that UA itself may participate
in calcium oxalate crystallization.
Recently, we reported the partial biochemical and physico-
chemical characterization of naturally occurring organic macro-
molecules in urine that demonstrate marked inhibitor activity
for calcium oxalate nucleation [151. In the present study, we
have evaluated whether or not UA and the various urate salts
could attenuate the inhibitory activity of these naturally occur-
ring macromolecules with respect to calcium oxalate nucleation
and crystal growth.
Methods
Preparation of naturally occurring inhibitor. The isolation
and partial purification of the various urinary organic macro-
molecules has been described previously [15]. Briefly, the
procedure consisted of successive Millipore filtration of three to
five combined 24-hr urine specimens from normal subjects
through a 0.8- and 0.45-xm Gelman Industrial filter. The filtrate
was ultrafiltered through a 50,000-dalton hollow fiber filter
838
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Fig. 1. Effect of various urate phases on the fraction-of-macromol-
ecu/es-(Y-b) -promoted inhibitor activity of calcium oxalate nucleation.
The formation product ratio of calcium oxalate was determined in the
filtrates after the standard solution containing Y-b (0.025 mg/mI) was
incubated with varying amounts of the urate phases expressed as
crystal surface area per milliliter. The numbers in parentheses for
monopotassium urate (KU) represent the crystal surface areas at those
points (note broken scale). Results were compared with the formation
product ratio, obtained in the presence of Y-b without prior incubation
with the urate phases: * < 0.005, < 0.025 by Student's t test. Bars
indicate mean 5E.
(Amicon Corporation, Lexington, Massachusetts). The filtrate
so-collected was again ultrafiltered through a 5,000-dalton hol-
low fiber filter until the volume was reduced to 1 dl. After it was
washed with distilled water four times, the retentate was
concentrated to a volume of 30 ml and centrifuged at x 12, lOOg
for 10 mm at 4°C. The supernatant was removed carefully and
applied to a Sephadex G-200 column. Based upon the protein
elution profile, several fractions were collected into four sub-
groups, designated Y-a, Y-b, Y-bc, and Y-c. Each subgroup
material was then dialyzed against distilled water for 2 days and
lyophilized. The lyophilized materials were weighed and stored
at —20°C until further study. For this study only the Y-b
fraction was used as the source of organic macromolecules
since it not only had marked inhibitory activity on calcium
oxalate nucleation but also had the greatest yield of material of
the four subgroups. The Y-b material from each preparation
was found to be identical in composition by electrophoresis in
10% sodium dodecyl sulfate polyacrylamide gel (data not
shown).
Formation product ratio (FPR) of calcium oxalate. The effect
of crystalline UA, NaU, and potassium urate (KU) on the
inhibitory activity of the Y-b fraction on calcium oxalate
nucleation was performed by the same procedure previously
described [161. Briefly, UA or NaU was added in varying
amounts (0.10 to 2 mg/mi) to the synthetic solution (1 mM
CaCl2, 2 mrs't MgC12, 5 mtt sodium cacodyiate, and 136 mM
NaC1) containing 0.025 mg of Y-b fraction/mi. The solid phase
was removed by Millipore filtration after 2 hr of incubation. The
FPR of calcium oxalate was then determined for the filtrate by
adding an increasing amount of soluble oxalate (as sodium
oxalate). The FPR represented the minimum supersaturated
state which allowed precipitation of calcium oxalate at 3 hr,
where a value of 1 indicated saturation, greater than 1 supersat-
uration, and less than 1 undersaturation. All studies were
performed at pH 6.5 except for UA where a pH of 5.3 was used
(26.2) because of the instability of UA at the higher pH [5]. To assess
the effect of KU, a solution saturated with respect to KU was
used instead of the above synthetic medium to prevent the
dissolution of KU. Purified KU seed (2 mg/mI) was incubated
for 2 days in the synthetic medium, in which potassium chloride
replaced sodium chloride. After incubation the filtrate was
obtained by passing the material through the 0.8 xm Gelman
filter. The FPR of calcium oxalate was then determined in the
filtrate.
Crystal growth of calcium oxalate. The method for estimating
the crystal growth is similar to that previously described [16]. A
known amount of calcium oxalate was added to a solution
which was metastably supersaturated with respect to calcium
oxalate containing 147 mmoles sodium and 0.44 mmoles calci-
um and oxalate/liter. The growth of added calcium oxalate was
determined from the difference between the total calcium
concentration at saturation and at various times after seeding.
By plotting the change in total calcium concentration versus
time, a linear relationship is derived, the slope of which (k)
represents the rate constant for the crystal growth of calcium
oxalate [17] expressed as M1 min' (mg/dl'. Thus a decline
in k represents an inhibition of seeded calcium oxalate growth.
The effect of the Y-b fraction on the crystal growth was
evaluated as above after the addition of increasing amounts of
the macromolecule from 0.025 to 1.00 mg/ml. The attenuation of
the inhibitory effect of Y-b on the crystal growth of calcium
oxalate by UA and the urate salts was evaluated by the addition
of increasing amounts (0.1 to 2 mg/ml) of the solid phase to the
test solution containing Y-b at a concentration of 0.025 mg/mI.
The test solution was comprised of 147 mrvi NaCl or KC1 and
0.44 m Ca as CaC12. After 2 hr of incubation the solid phase
was removed by 0.8 m Gelman filtration. Oxalate as the
sodium salt was added to achieve a concentration of 0.44 mM.
The solution was then seeded with calcium oxalate (0.7 mg/mI)
to initiate crystal growth. All studies were performed at pH 6.5
except for the UA study which was accomplished at pH 5.3.
The data are expressed relative to the amount of crystal surface
area for each urate phase (crystal surface areas kindly determined
by Dr. B. Finlayson, Gainesville, Florida) and are represented by
NaU, 11.2 m2/g; KU, 26.2 m2/g; and UA, 2.1 m2/g.
Results
FPR of calcium oxalate (Fig. 1). Preliminary studies dis-
closed that the Y-b fraction at a concentration range of 0.025 to
KU
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Fig. 2. Effect of various urate phases on the fraction-of-macromol-
ecules-(Y-b) -induced inhibition of calcium oxalate crystal growth. The
crystal growth of calcium oxalate was determined in the filtrates, after
the standard solution containing Y-b (0.025 mg/mI) was incubated with
varying amounts of the urate phases, by the addition of calcium oxalate
seed (0,7 mg/mI). Results are expressed as the rate constant (k) for
crystal growth where a decline in k represents the inhibition of seeded
calcium oxalate growth. The numbers in parentheses for monopotas-
sium urate (KU) represent the crystal surface areas at those points (note
broken scale). Results were compared with k obtained in the presence
of Y-b without prior incubation with the urate phases: *p < 0.025, 55P
<0.0025, < 0.010 by Student's t test. Bars indicate mean SE.
0.1 mg/mI caused a progressive increase in the FPR of calcium
oxalate. Thus, the concentration of Y-b used in this study of
0.025 mg/mi caused a submaximal inhibition of the spontaneous
nucleation of calcium oxalate. Prior to incubation with UA or
the various urate phases, the Y-b fraction significantly in-
creased the FPR of calcium oxalate by 30 to 50% (from 8.0 to
10.5 and 12.0). This variation in the percent increase of the FPR
of calcium oxalate by the Y-b fraction probably represents
experimental variability since the Y-b fraction used in all
experiments was identical.
When the solution containing Y-b was preincubated with
NaU, as little as 1 .1 mm2/mi of the solid phase caused a decline
in the FPR of calcium oxalate from 12.0 to 11.0. Thus, this
procedure attentuated the inhibitor activity of Y-b from 50 to
38%. When the crystal surface area of NaU was increased to 5.6
mm2/mI, the FPR of calcium oxalate further declined to 10.2
(representing 28% inhibition).
A larger crystal surface area of KU or UA was required to
reduce the FPR of calcium oxalate. At a surface area of 1.1
mm2/ml, neither solid phase significantly altered the FPR of
calcium oxalate. However, at 2.1 mm2/ml of crystal surface
area, the FPR of calcium oxalate significantly declined from
30% inhibition to 19% for UA. KU required 26.2 mm2/ml of
crystal surface area to significantly attenuate the Y-b inhibition
of calcium oxalate nucleation from 40 to 28%. A further
reduction of the Y-b inhibitory activity to 13% was observed
when the KU crystal surface area was increased to 56.4 mm2/mi
(data not shown).
Crystal growth of calcium oxalate (Fig. 2). The addition of
Y-b at concentrations of 0.025 to 0.1 mg/mI to the calcium
oxalate growth system significantly reduced k or the rate of
crystal growth of calcium oxalate. The 0.025 mg/ml concentra-
tion of Y-b used produced a submaximal decline in the crystal
growth rate of an average of 39%.
In the NaU system, the crystal growth rate declined from 65
to 34 Mmin (mg/dlY1 when Y-b alone was added, repre-
senting an inhibition of 48%. The prior preincubation with 1.1
mm2/ml of NaU crystal increased the crystal growth rate to 44.
Thus, the inhibitory activity of Y-b was attenuated from 48 to
32%. Increasing the NaU crystal surface area even further
caused only a modest further effect on calcium oxalate crystal
growth.
For UA and KU phases, greater crystal surface areas were
required to significantly alter the crystal growth rate of calcium
oxalate. Thus, the crystal growth rate of calcium oxalate
increased significantly only when the UA crystal surface area
was increased to 2.1 mm2/ml or higher. The crystal growth rate
did not change significantly when the solution containing Y-b
was preincubated with a low amount of KU (2.6 mm2/ml).
However, at greater surface areas (> 13.1 mm2/ml) KU was
more effective than NaU in increasing the crystal growth rate.
Thus, KU (13.1 mm2/ml) increased k from 46 in the presence of
Y-b alone to 64, a value which closely approximated the control
value in the absence of Y-b, indicating that the attenuation of
inhibitor activity was nearly complete. Raising the KU crystal
surface area to 26.2 mm2/ml did not afford additional attenua-
tion of the Y-b inhibitory effect on crystal growth.
Discussion
This study provides additional support for the important
etiologic role of monosodium urate (NaU) in the formation of
calcium oxalate stones. It was previously shown that NaU can
attenuate the inhibitory effect of glycosaminoglycans on the
spontaneous heterogeneous nucleation of calcium oxalate [9,
II, 181. However, heparin had been utilized as a standard
glycosaminoglycan although it is not considered to be a major
glycosaminoglycan found in urine. Thus, the question remains
as to whether or not the inhibitory activity of naturally occur-
ring urinary organic macromolecules is subject to attenuation
by the urate salts.
We have previously reported the separation and partial
characterization of naturally occurring organic substances
found in urine which have inhibitory activity toward calcium
oxalate nucleation and crystal growth [15]. In this study, we
have shown that the inhibitory activity of these naturally
occurring substances can be attenuated by various urate
phases. Monosodium urate was found to be most effective in
attenuating the Y-b inhibitory activity for calcium oxalate
nucleation and crystal growth. This finding supports a previous
report using a model glycosaminoglycan (heparin) 18] in which
a prominent role of NaU was involved. Unlike that report,
however, KU and UA were also found to attenuate the inhibi-
tory action of Y-b, though only at much higher total crystal
surface areas than those used for NaU.
Despite the ability of KU to attenuate the inhibitory activity
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of Y-b, this urate phase probably does not play an important
pathogenetic role in the formation of calcium oxalate stones.
Although KU is stable in the range of urinary pH typically
encountered in hyperuricosuric calcium oxalate nephrolithiasis
[5], its formation in urine is unlikely because of urinary under-
saturation with respect to this phase [18] owing to a relatively
high solubility of KU. In contrast, the findings of this study
support a potential etiologic role of UA in calcium oxalate
crystallization, since the urinary concentration of undissociated
uric acid has been reported to be increased in patients with
hyperuricosuric calcium oxalate nephrolithiasis [13].
The mechanism by which NaU and to a lesser extent KU and
UA attenuated the inhibitory action of Y-b is unknown. In
previous studies [11] it was possible to demonstrate that the
glycosaminoglycan was bound to NaU. In the present study no
determination of this nature was performed.
Taken together, the results demonstrate that the inhibitory
activity of naturally occurring urinary organic macromolecules
toward calcium oxalate nucleation and crystal growth can be
attenuated by the various urate phases and UA. In light of the
prominent activity demonstrated by NaU, the marked supersat-
uration of urine with respect to this urate phase and its ability to
induce heterogeneous nucleation of calcium oxalate, NaU
appears to be the major urate phase of pathogenetic importance
in the development of hyperuricosuric calcium oxalate
nephrolithiasis.
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